Also categorized in General:
Immunological Resolution of Human Chronic Graft-versus-Host Disease.
x hide permanently

World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trial

The Institute of Cancer Research, London

A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown. It is the first time that a Phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.

Mentions: Immunotherapy